Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients
Immunotherapy with immune checkpoint inhibitors for non-small cell lung cancer (NSCLC) has emerged as an important treatment option. Although immunotherapy may significantly improve survival and quality of life, response rates are as low as 20% in NSCLC patients.
